Cargando…

RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery

Detalles Bibliográficos
Autores principales:	Fagotti, A, Vizzielli, G, Petrillo, M, Scambia, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154694/ https://www.ncbi.nlm.nih.gov/pubmed/27995174 http://dx.doi.org/10.1016/j.gore.2016.11.003

Ejemplares similares

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
por: Tsonis, Orestis, et al.
Publicado: (2020)

Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
por: Abbas-Aghababazadeh, Farnoosh, et al.
Publicado: (2023)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
por: Ferrandina, G, et al.
Publicado: (2009)

Postoperative paralytic ileus following debulking surgery in ovarian cancer patients
por: Egger, Eva K., et al.
Publicado: (2022)

Impact of surgeon learning curve in minimally invasive radical hysterectomy on early stage cervical cancer patient survival
por: Pedone Anchora, L, et al.
Publicado: (2021)

What is paracervical lymphadenectomy?
por: Querleu, Denis, et al.
Publicado: (2021)

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control
por: Petrillo, Marco, et al.
Publicado: (2016)

An invited commentary on ‘Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study’
por: Coppola, Alessandro, et al.
Publicado: (2023)

Laparoscopic selection for surgery in epithelial ovarian cancer. A short review
por: Ghirardi, v, et al.
Publicado: (2023)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Secondary debulking for ovarian carcinoma relapse: The R-R dilemma – is the prognosis different for residual or recurrent disease?
por: Spiliotis, John D., et al.
Publicado: (2019)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery
por: Eoh, Kyung Jin, et al.
Publicado: (2016)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Total parietal peritonectomy in primary debulking surgery for advanced ovarian cancer
por: Yokosu, Kota, et al.
Publicado: (2021)

Diaphragm hernia after debulking surgery in patients with ovarian cancer
por: Ehmann, Sarah, et al.
Publicado: (2021)

Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer
por: Arab, Maliheh, et al.
Publicado: (2018)

Does Endometriosis Hinder Successful Ovarian Debulking Surgery?
por: Sananpanichkul, Panya, et al.
Publicado: (2018)

The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC)
por: Asp, Mihaela, et al.
Publicado: (2022)

Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer
por: Derlatka, Pawel, et al.
Publicado: (2016)

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’
por: Chen, Yuan, et al.
Publicado: (2023)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Total Microlaparoscopic Radical Hysterectomy in Early Cervical Cancer
por: Fanfani, Francesco, et al.
Publicado: (2013)

How I do it: Radical debulking of lower extremity end-stage lymphedema
por: Singh, Kuldeep, et al.
Publicado: (2023)

Does cavity margin shaving reduce residual tumor and re‐excision rates? A systematic review
por: Fernandez‐Pacheco, M., et al.
Publicado: (2022)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

Robotic interval debulking with radical hysterectomy and partial urinary bladder resection for locally advanced carcinosarcoma of the uterus
por: Harold, Justin, et al.
Publicado: (2022)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
por: Nakamura, Kazuto, et al.
Publicado: (2020)

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
por: Braicu, E-I, et al.
Publicado: (2011)

Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
por: Günakan, Emre, et al.
Publicado: (2020)

The Radical Treatment of Hydrocele
por: Apte, Y. G.
Publicado: (1907)

Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
por: Angeles, Martina Aida, et al.
Publicado: (2021)

SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
por: Bååth, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8ltpadvmh20qkf81j98svd9377